The FDA's announcement on Monday came just two weeks after a panel of outside scientific advisers voted 8 to 2 to recommend that the agency approve the drug for patients with erythema nodosum leprosum, or ENL, a complication of leprosy that causes skin lesions, fever and other symptoms.
32.
The FDA panel is in the second day of its consideration of the thalidomide drug made by Warren New Jersey-based Celgene, for use in a skin condition called erythema nodosum leprosum, or ENL . A rare complication of leprosy, ENL causes painful nodules which can cause infection, scarring or skin ulcers.
